Expression and function of the K + channel KCNQ genes in human arteries

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 42-53

  Ng, Fu Liang ^a   Davis, Alison J ^a   Jepps, Thomas A ^a   Harhun, Maksym I ^a   Yeung, Shuk Yin ^a   Wan, Andrew ^b   Reddy, Marcus ^b   Melville, David ^b   Nardi, Antonio ^c   Khong, Teck K ^a   Greenwood, Iain A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c NEUROSEARCH A S   (Denmark)

Author keywords

arterial tone; human; K v7; KCNQ; vascular smooth muscle

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; CHROMANOL 293B; LINOPIRDINE; N [1 (3 MORPHOLINOPHENYL)ETHYL] 3 PHENYLPROP 2 ENAMIDE; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE; UNCLASSIFIED DRUG;

ADULT; ARTERY MUSCLE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG MECHANISM; ELECTIVE SURGERY; ELECTROMYOGRAPHY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MALE; MESENTERIC ARTERY; MUSCLE ISOMETRIC CONTRACTION; POTASSIUM CURRENT; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTILITY; TISSUE DISTRIBUTION;

AGED; ARTERIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KCNQ POTASSIUM CHANNELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 78650107531     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01027.x     Document Type: Article

References (34)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bentzen BH, Schmitt N, Calloe K, Dalby Brown W, Grunnet M, Olesen SP, (2006). The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology 51: 1068-1077.
3. Bett GC, Morales MJ, Beahm DL, Duffey ME, Rasmusson RL, (2006). Ancillary subunits and stimulation frequency determine the potency of chromanol 293B block of the KCNQ1 potassium channel. J Physiol 576: 755-767.
4. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE, (2005). Retigabine: chemical synthesis to clinical application. CNS Drug Rev 11: 1-20.
5. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL, (2009). Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 76: 1053-1061.
6. Dalby-Brown W, Hansen HH, Korsgaard MPG, Mirza N, Olesen SP, (2006). Kv7 channels: functions, pharmacology and channel modulators. Curr Top Med Chem 6: 999-1023.
7. Greenwood IA, Ohya S, (2009). New tricks for old dogs: KCNQ expression and function in smooth muscle. Br J Pharmacol 156: 1196-1203.
8. Harhun MI, Szewczyk K, Laux H, Prestwich SA, Gordienko DV, Moss RF, et al. (2009). Interstitial cells from rat middle cerebral artery belong to smooth muscle cell type. J Cell Mol Med 13: 4532-4539.
9. Herrmann WM, Kern U, Aigner M, (1987). On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad Med J 63: 87-103.
10. Hummel T, Friedmann T, Pauli E, Niebch G, Borbe HO, Kobal G, (1991). Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol 32: 69-76.
11. Jentsch TJ, (2000). Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30.
12. Jepps TA, Greenwood IA, Moffatt JD, Sanders KM, Ohya S, (2009). Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol 297: G107-G115.
13. Joshi S, Balan P, Gurney AM, (2006). Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7: 31.
14. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM, (2009). KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368-376.
15. + channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97: 4333-4338.
16. Knollmann BC, Sirenko S, Rong Q, Katchman AN, Casimiro M, Pfeifer K, et al. (2007). Kcnq1 contributes to an adrenergic-sensitive steady-state K+ current in mouse heart. Biochem Biophys Res Commun 360: 212-218.
17. Mackie AR, Byron KL, (2008). Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol 74: 1171-1179.
18. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, et al. (2008). Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475-483.
19. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA, (2000). Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262.
20. Mulvany MJ, Halpern W, (1977). Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
21. Ohya S, Sergeant G, Greenwood IA, Horowitz B, (2003). Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res 92: 1016-1023.
22. Pfaffl MW, (2001). A new mathematical model for relative quantification in real-time PCR. Nucleic Acids Res 29: 2002-2007.
23. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM, (2007). Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68: 1197-1204.
24. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al. (1996). Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 384: 80-83.
25. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, et al. (2005). Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 25: 5051-5060.
26. Ks channels to the cognitive enhancer XE991. Mol Pharmacol 57: 1218-1223.
27. Wilde AAM, Bezzina CR, (2005). Genetics of cardiac arrhythmias. Heart 91: 1352-1358.
28. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H, (2005). The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67: 1009-1017.
29. Yeung SY, Greenwood IA, (2005). Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 146: 585-595.
30. v7 channels in murine vascular reactivity. Br J Pharmacol 151: 758-770.
31. Yeung SYM, Lange W, Schwake M, Greenwood IA, (2008a). Expression profile and characterization of a truncated KCNQ5 splice variant. Biochem Biophys Res Commun 371: 741-746.
32. + currents. Br J Pharmacol 155: 62-72.
33. Yus-Nájera E, Muñoz A, Salvador N, Jensen BS, Rasmussen HB, Defelipe J, et al. (2003). Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience 120: 353-364.
34. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, et al. (2010). Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 588: 3277-3293.